Trials / Completed
CompletedNCT02610361
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-283 | In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme. In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types |
Timeline
- Start date
- 2013-11-20
- Primary completion
- 2017-10-01
- Completion
- 2017-10-01
- First posted
- 2015-11-20
- Last updated
- 2024-12-27
Locations
19 sites across 2 countries: Australia, New Zealand
Source: ClinicalTrials.gov record NCT02610361. Inclusion in this directory is not an endorsement.